Anticoagulant effects of protein C, protein S, and antithrombin levels on the protein C pathway in young children.
Antithrombin
Developmental hemostasis
Protein C
Protein S
Thrombin generation
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
11
10
2023
accepted:
27
12
2023
revised:
22
12
2023
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
16
1
2024
Statut:
aheadofprint
Résumé
The protein C (PC) pathway involves physiological anticoagulant factors (PC, protein S [PS], and factor V) and performs major anticoagulant functions in adults. Variations in overall PC pathway function due to dynamic changes in PC and PS in early childhood are poorly understood. We aimed to evaluate the contributions of PC pathway function during early childhood by measuring changes in plasma thrombin generation (TG) after administration of the PC activator protac. We evaluated correlations between anticoagulant factors and percentage of protac-induced coagulation inhibition (PiCi%). Before protac addition, TG in newborns (n = 35), infants (n = 42), young children (n = 35), and adults (n = 20) were 525 ± 74, 720 ± 96, 785 ± 53, and 802 ± 64 mOD/min, and PiCi% were 42.1 ± 9.9, 69.8 ± 11.0, 82.9 ± 4.4, and 86.9 ± 3.4%, respectively. The distribution of PiCi% on the two axes of TG (with or without protac) changed continuously with age and differed from that of warfarin-treated plasma and adult PC- or PS-deficient plasma. PiCi% increased dynamically during infancy and correlated with PS levels in newborns and PC levels in young children. Addition of PC or fresh frozen plasma equivalent to approximately 25% PC to PC-deficient plasma improved PiCi%. This automatic measurement requires only a small sample volume and is useful for analysis of developmental hemostasis.
Identifiants
pubmed: 38228939
doi: 10.1007/s12185-023-03699-4
pii: 10.1007/s12185-023-03699-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 17ek0109210h0001
Organisme : Japan Agency for Medical Research and Development
ID : 20ek0109481h0001
Informations de copyright
© 2024. Japanese Society of Hematology.
Références
Andrew M. Developmental hemostasis: relevance to hemostatic problems during childhood. Semin Thromb Hemost. 1995;21(4):341–56.
doi: 10.1055/s-2007-1000655
pubmed: 8747697
Toulon P. Developmental hemostasis: laboratory and clinical implications. Int J Lab Hematol. 2016;38(Suppl 1):66–77.
doi: 10.1111/ijlh.12531
pubmed: 27426861
Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost. 2013;11(10):1850–4.
doi: 10.1111/jth.12372
pubmed: 23927605
Monagle P, Ignjatovic V, Savoia H. Hemostasis in neonates and children: pitfalls and dilemmas. Blood Rev. 2010;24(2):63–8.
doi: 10.1016/j.blre.2009.12.001
pubmed: 20074839
Rey Y, Formoso V, Barreto Mota R, Soares H. Developmental hemostasis in the neonatal period. World J Pediatr. 2022;18(1):7–15.
doi: 10.1007/s12519-021-00492-3
Araki S, Shirahata A. Vitamin K deficiency bleeding in infancy. Nutrients. 2020;12(3):780.
doi: 10.3390/nu12030780
pubmed: 32187975
pmcid: 7146284
Eliwan H, Omer M, McKenna E, Kelly LA, Nolan B, Regan I, et al. Protein C pathway in paediatric and neonatal Sepsis. Front Pediatr. 2022;9: 562495.
doi: 10.3389/fped.2021.562495
pubmed: 35186813
pmcid: 8849213
Ohga S, Kang D, Kinjo T, Ochiai M, Doi T, Ishimura M, et al. Paediatric presentation and outcome of congenital protein C deficiency in Japan. Haemophilia. 2013;19(3):378–84.
doi: 10.1111/hae.12097
pubmed: 23379934
Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res. 2009;124(1):137–43.
doi: 10.1016/j.thromres.2008.11.017
pubmed: 19157524
Ruzicka K, Kapiotis S, Quehenberger P, Handler S, Pabinger-Fasching I, Mannhalter C, et al. Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway. Thromb Res. 1997;87(6):501–10.
doi: 10.1016/S0049-3848(97)00179-5
pubmed: 9330432
Hashimoto N, Ogiwara K, Shimonishi N, Nakagawa T, Nakajima Y, Furukawa S, et al. Screening of the protein C pathway abnormality-related thrombophilia by using thrombomodulin-mediated tissue factor-triggered clot waveform analysis. Eur J Haematol. 2022;109(1):100–8.
doi: 10.1111/ejh.13777
pubmed: 35430749
Aoki H, Ogiwara K, Hasegawa M, Nogami K. Hemostatic rebalance in neonatal intrahepatic cholestasis with citrin deficiency. Pediatr Int. 2022;64(1): e14741.
doi: 10.1111/ped.14741
pubmed: 33851467
Ogiwara K, Nogami K, Mizumachi K, Nakagawa T, Noda N, Ohga S, et al. Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency. Int J Hematol. 2019;109(6):650–6.
doi: 10.1007/s12185-019-02645-7
pubmed: 30963470
Rogalski P, Rogalska-Plonska M, Wroblewski E, Kostecka-Roslen I, Dabrowska M, Swidnicka-Siergiejko A, et al. Laboratory evidence for hypercoagulability in cirrhotic patients with history of variceal bleeding. Thromb Res. 2019;178:41–6.
doi: 10.1016/j.thromres.2019.03.021
pubmed: 30959281
Arachchillage DJ, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M. Thrombophilia testing: a British Society for Haematology guideline. Br J Haematol. 2022;198(3):443–58.
doi: 10.1111/bjh.18239
pubmed: 35645034
pmcid: 9542828
Hashimoto N, Ogiwara K, Matsumoto T, Furukawa S, Takeyama M, Nogami K. Characterization of thrombophilia-related plasmas evaluated by anticoagulants-mediated thrombin and plasmin generation assays. Blood Coagul Fibrinolysis. 2022;33(6):327–36.
doi: 10.1097/MBC.0000000000001148
pubmed: 35981254